• Home
  • Chongqing Peg-Bio Biopharm Co., Ltd.

Chongqing Peg-Bio Biopharm Co., Ltd.

About Chongqing Peg-Bio Biopharm Co., Ltd.

Read more Show less
Categories
more categories Show less
  • CN
  • 2023
    On CPHI since
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI & PMEC China 2024

Shanghai New International Expo Center
19 - 21 June 2024
View Exhibitor Profile

Products from Chongqing Peg-Bio Biopharm Co., Ltd. (1)

  • Semaglutide Intermediate (Recombinant)

    Product Semaglutide Intermediate (Recombinant)

    Semaglutide is a new 2nd Generation GLP-1RA drug developed by Novo Nordisk. In Dec. 2019, Semaglutide injection (brand name: Ozempic, 4mg/3ml) was approved by FDA to improve glycemic control in adults with type 2 diabetes. In Jun. 2021, Semaglutide injection (brand name: Wegovy, 2.4mg/dose) was approved by...